OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Feldman on the Utility of Personalized Medicine in Breast Cancer Management

October 29th 2024

Sheldon M. Feldman, MD, discusses how the use of personalized medicine has evolved in breast cancer management.

Dr Cosgrove on the Evolution of ADC Treatment in Ovarian Cancer

October 29th 2024

Casey M. Cosgrove, MD, discusses the evolution of treatment with antibody-drug conjugates for patients with ovarian cancer.

Dr Parikh on Currently Available Targeted Treatment Approaches for Mutated CRC

October 29th 2024

Aparna Parikh, MD, discusses currently available targeted therapy options for patients with colorectal cancer.

Dr Lotan on Factors Informing Treatment Selection in BCG-Unresponsive NMIBC

October 28th 2024

Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.

Dr Tan on the Selection of IO-Based Combination Regimens in Advanced RCC

October 28th 2024

Alan Tan, MD, discusses long-term data guiding the selection of immuno-oncology combination regimens in advanced renal cell carcinoma.

Dr Herrera on Nivolumab vs Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

October 28th 2024

Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.

Dr Herbst on Notable Research Avenues for Patients With Unmutated NSCLC

October 28th 2024

Roy S. Herbst, MD, PhD, discusses ongoing, planned, and future research for the management of unmutated non–small cell lung cancer.

Dr Feldman on Breast Cancer Awareness Month and Early Screening/Detection

October 28th 2024

Sheldon M. Feldman, MD, discusses the importance of Breast Cancer Awareness Month as well as timely screening and early detection.

Dr Chambers on the Importance of Patient Counseling in Ovarian Cancer

October 25th 2024

Laura J. Chambers, DO, discusses the importance of treatment counseling for patients with ovarian cancer considering PARP inhibitor therapy.

Dr Westbrook on the Evolving Understanding of Non–Clear Cell RCC Subtypes

October 25th 2024

Thomas Westbrook, MD, discusses the evolving understanding of non–clear cell renal cell carcinoma subtypes and implications for clinical practice.

Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer

October 25th 2024

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC

October 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Dr Nooka on Integrating Bispecific Antibodies Into the Community Treatment Paradigm for Multiple Myeloma

October 25th 2024

Ajay K. Nooka, MD, MPH, FACP, discusses the integration of bispecific antibodies into the community treatment paradigm for multiple myeloma.

Dr Inra on the Role of the Surgeon in Early-Stage Lung Cancer

October 25th 2024

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.

Dr Miller on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

October 25th 2024

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC

October 25th 2024

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer

October 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.

Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in DLBCL

October 25th 2024

Farrukh Awan, MD, discuses the evolving role of bispecific antibodies in the treatment paradigm of diffuse large B-cell lymphoma.

Dr Battiwalla on Limitations to CAR T-Cell Therapy Access in Hematologic Malignancies

October 24th 2024

Minoo Battiwalla, MD, MS, discusses both the benefits and the limitations of treatment with CAR T-cell therapy across hematologic malignancies.

Dr Ma on Interim Efficacy and Safety Data With RLY-2608 in PI3Kα-Mutant HR+/HER2– Breast Cancer

October 24th 2024

Cynthia X. Ma, MD, PhD, discusses positive interim data from the phase 1 ReDiscover trial in PI3Kα-mutated HR-positive, HER2-negative breast cancer.